Entresto (sacubitril plus valsartan) is now available for adults with symptomatic chronic heart failure with reduced ejection fraction. Novartis says that sacubitril plus valsartan reduces the risk of cardiovascular death and first hospitalisation for heart failure by 20 per cent when compared to enalapril, equivalent to an absolute risk reduction of 4.7 per cent.
This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.
We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.
